EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.

Anders Gülfe; JOHAN KARLSSON WALLMAN; Lars Erik Kristensen

doi:10.1186/s13075-016-0950-0

EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.

Anders Gülfe, JOHAN KARLSSON WALLMAN, Lars Erik Kristensen

Copenhagen University Hospital

Research output: Contribution to journal › Article › peer-review

Abstract

The development of EuroQol-5 dimensions (EQ-5D) utility over time in rheumatoid arthritis (RA) patients, treated with biologics other than tumour necrosis factor inhibitors (TNFi), based on the standard British (UK) and the new Swedish (SE) EQ-5D preference sets, has not been previously described.

Original language	English
Article number	51
Journal	Arthritis Research and Therapy
Volume	18
Issue number	1
DOIs	https://doi.org/10.1186/s13075-016-0950-0
Publication status	Published - 2016

Subject classification (UKÄ)

Rheumatology and Autoimmunity

Access to Document

10.1186/s13075-016-0950-0

http://www.ncbi.nlm.nih.gov/pubmed/26892115?dopt=Abstract

Fingerprint

Dive into the research topics of 'EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.'. Together they form a unique fingerprint.

Cite this

Gülfe, A., KARLSSON WALLMAN, JOHAN., & Kristensen, L. E. (2016). EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden. Arthritis Research and Therapy, 18(1), Article 51. https://doi.org/10.1186/s13075-016-0950-0

@article{78e367530dbd4f59831cf8468e5fe341,

title = "EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.",

abstract = "The development of EuroQol-5 dimensions (EQ-5D) utility over time in rheumatoid arthritis (RA) patients, treated with biologics other than tumour necrosis factor inhibitors (TNFi), based on the standard British (UK) and the new Swedish (SE) EQ-5D preference sets, has not been previously described.",

author = "Anders G{\"u}lfe and {KARLSSON WALLMAN}, JOHAN and Kristensen, {Lars Erik}",

year = "2016",

doi = "10.1186/s13075-016-0950-0",

language = "English",

volume = "18",

journal = "Arthritis Research and Therapy",

issn = "1478-6362",

publisher = "BioMed Central (BMC)",

number = "1",

}

Gülfe, A , KARLSSON WALLMAN, JOHAN & Kristensen, LE 2016, 'EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.', Arthritis Research and Therapy, vol. 18, no. 1, 51. https://doi.org/10.1186/s13075-016-0950-0

EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden. / Gülfe, Anders ; KARLSSON WALLMAN, JOHAN; Kristensen, Lars Erik.
In: Arthritis Research and Therapy, Vol. 18, No. 1, 51, 2016.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.

AU - Gülfe, Anders

AU - KARLSSON WALLMAN, JOHAN

AU - Kristensen, Lars Erik

PY - 2016

Y1 - 2016

N2 - The development of EuroQol-5 dimensions (EQ-5D) utility over time in rheumatoid arthritis (RA) patients, treated with biologics other than tumour necrosis factor inhibitors (TNFi), based on the standard British (UK) and the new Swedish (SE) EQ-5D preference sets, has not been previously described.

AB - The development of EuroQol-5 dimensions (EQ-5D) utility over time in rheumatoid arthritis (RA) patients, treated with biologics other than tumour necrosis factor inhibitors (TNFi), based on the standard British (UK) and the new Swedish (SE) EQ-5D preference sets, has not been previously described.

U2 - 10.1186/s13075-016-0950-0

DO - 10.1186/s13075-016-0950-0

M3 - Article

C2 - 26892115

SN - 1478-6362

VL - 18

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

IS - 1

M1 - 51

ER -